{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:26:18Z","timestamp":1779290778211,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To establish refined risk prediction models for mortality in patients with microscopic polyangiitis (MPA) by using comprehensive clinical characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from the multicentre Japanese registry of patients with vasculitis (REVEAL cohort) were used in our analysis. In total, 194 patients with newly diagnosed MPA were included, and baseline demographic, clinical, laboratory, and treatment details were collected. Univariate and multivariate analyses were conducted to identify the significant risk factors predictive of mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over a median follow-up of 202.5 (84\u2013352) weeks, 60 (30.9%) of 194 patients died. The causes of death included MPA-related vasculitis (18.3%), infection (50.0%), and others (31.7%). Deceased patients were older (median age 76.2 years) than survivors (72.3 years) (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.0001). The death group had shorter observation periods (median 128.5 [35.3\u2013248] weeks) than the survivor group (229 [112\u2013392] weeks). Compared to survivors, the death group exhibited a higher smoking index, lower serum albumin levels, higher serum C-reactive protein levels, higher Birmingham Vasculitis Activity Score (BVAS), higher Five-Factor Score, and a more severe European Vasculitis Study Group (EUVAS) categorization system. Multivariate analysis revealed that higher BVAS and severe EUVAS independently predicted mortality. Kaplan\u2013Meier survival curves demonstrated lower survival rates for BVAS \u226520 and severe EUVAS, and a risk prediction model (RPM) based on these stratified patients into low, moderate, and high-risk mortality groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The developed RPM is promising to predict mortality in patients with MPA and provides clinicians with a valuable tool for risk assessment and informed clinical decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-023-03210-8","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T06:01:43Z","timestamp":1700460103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Risk prediction model for mortality in microscopic polyangiitis: multicentre REVEAL cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Takuya","family":"Kotani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayana","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryu","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaho","family":"Gon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikihito","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichiro","family":"Kadoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Hiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"issue":"1","key":"3210_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1\u201311.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"3210_CR2","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1093\/rheumatology\/ker112","volume":"50","author":"L Corral-Gudino","year":"2011","unstructured":"Corral-Gudino L, Borao-Cengotita-Bengoa M, Del Pino-Montes J, Lerma-M\u00e1rquez JL. Overall survival, renal survival and relapse in patients with microscopic polyangiitis: a systematic review of current evidence. Rheumatology (Oxford). 2011;50(8):1414\u201323.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"3210_CR3","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ejim.2010.09.005","volume":"21","author":"M Borao-Cengotita-Bengoa","year":"2010","unstructured":"Borao-Cengotita-Bengoa M, Corral-Gudino L, Del Pino-Montes J, Lerma-M\u00e1rquez JL. Long-term follow-up of microscopic polyangiitis, 17-year experience at a single center. Eur J Intern Med. 2010;21(6):542\u20137.","journal-title":"Eur J Intern Med"},{"issue":"5 Suppl 51","key":"3210_CR4","first-page":"S94","volume":"26","author":"R Phillip","year":"2008","unstructured":"Phillip R, Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S94-104.","journal-title":"Clin Exp Rheumatol"},{"key":"3210_CR5","first-page":"65","volume":"36","author":"CH Mun","year":"2018","unstructured":"Mun CH, Yoo J, Jung SM, Song JJ, Park YB, Lee SW. The initial predictors of death in 153 patients with ANCA-associated vasculitis in a single Korean centre. Clin Exp Rheumatol. 2018;36:65\u201372.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"3210_CR6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/01.md.0000180793.80212.17","volume":"84","author":"A Bourgarit","year":"2005","unstructured":"Bourgarit A, Toumelin PL, Pagnoux C, Cohen P, Mahr A, Guern VL, Mouthon L, French Vasculitis Study Group, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore). 2005;84(5):323\u201330.","journal-title":"Medicine (Baltimore)."},{"issue":"3","key":"3210_CR7","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/1756-185X.14532","volume":"26","author":"Y Takakuwa","year":"2023","unstructured":"Takakuwa Y, Yamasaki Y, Matsushita H, Kiyokawa T, Mizushima M, Tonooka K, et al. Long-term survival, causes of death, and prognostic factors for mortality in patients with microscopic polyangiitis and those with anti-neutrophil cytoplasmic antibody-positive interstitial lung disease: a single-center retrospective study. Int J Rheum Dis. 2023;26(3):446\u201353.","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"3210_CR8","first-page":"293","volume":"37","author":"Y Gu","year":"2022","unstructured":"Gu Y, Zhang T, Peng M, Shi JH. Characteristics and prognosis of microscopic polyangiitis patients with diffuse alveolar hemorrhage and interstitial lung disease. Chin Med Sci J. 2022;37(4):293\u2013302.","journal-title":"Chin Med Sci J"},{"key":"3210_CR9","doi-asserted-by":"publisher","first-page":"102467","DOI":"10.1016\/j.jaut.2020.102467","volume":"112","author":"Y Nguyen","year":"2020","unstructured":"Nguyen Y, Pagnoux C, Karras A, Qu\u00e9m\u00e9neur T, Maurier F, Hamidou M, French Vasculitis Study Group, et al. Microscopic polyangiitis: clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry. J Autoimmun. 2020;112:102467.","journal-title":"J Autoimmun."},{"issue":"1","key":"3210_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3109\/0886022X.2012.736069","volume":"35","author":"Q Wang","year":"2013","unstructured":"Wang Q, Mou S, Xu W, Qi C, Ni Z. Predicting mortality in microscopic polyangiitis with renal involvement: a survival analysis based on 64 patients. Ren Fail. 2013;35(1):82\u20137.","journal-title":"Ren Fail"},{"issue":"1","key":"3210_CR11","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/s41598-021-81311-7","volume":"11","author":"S Matsuda","year":"2021","unstructured":"Matsuda S, Kotani T, Suzuka T, Kiboshi T, Fukui K, Wakama M, et al. Evaluation of poor prognostic factors of respiratory related death in microscopic polyangiitis complicated by interstitial lung disease. Sci Rep. 2021;11(1):1490.","journal-title":"Sci Rep"},{"issue":"12","key":"3210_CR12","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2008.101279","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3210_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1136\/ard.2006.062711","volume":"66","author":"B Hellmich","year":"2007","unstructured":"Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66(5):605\u201317.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3210_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","volume":"90","author":"L Guillevin","year":"2011","unstructured":"Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Toumelin PL, French Vasculitis Study Group (FVSG). The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90(1):19\u201327.","journal-title":"Medicine (Baltimore)."},{"issue":"1","key":"3210_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13075-017-1506-7","volume":"20","author":"Y Sugiyama","year":"2018","unstructured":"Sugiyama Y, Yoshimi R, Tamura M, Takeno M, Kunishita Y, Kishimoto D, et al. The predictive prognostic factors for polymyositis\/dermatomyositis-associated interstitial lung disease. Arthritis Res Ther. 2018;20(1):7.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"3210_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/art.41566","volume":"73","author":"T Gono","year":"2021","unstructured":"Gono T, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Ikeda K, the Multicenter Retrospective Cohort of Japanese Patients with Myositis-Associated ILD (JAMI) Investigators, et al. Risk prediction modeling based on a combination of initial serum biomarker levels in polymyositis\/dermatomyositis-associated interstitial lung disease. Arthritis Rheumatol. 2021;73(4):677\u201386.","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"3210_CR17","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/rheumatology\/keq400","volume":"50","author":"R Suppiah","year":"2011","unstructured":"Suppiah R, Mukhtyar C, Flossmann O, Alberici F, Baslund B, Batra R, et al. A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology (Oxford). 2011;50(5):899\u2013905.","journal-title":"Rheumatology (Oxford)."},{"issue":"7","key":"3210_CR18","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/acr.23912","volume":"72","author":"R Solans-Laqu\u00e9","year":"2020","unstructured":"Solans-Laqu\u00e9 R, Rodriguez-Carballeira M, Rios-Blanco JJ, Fraile G, S\u00e1ez-Comet L, Martinez-Zapico A, Spanish Registry of Systemic Vasculitis, the Autoimmune Systemic Diseases Study Group, and the Spanish Society of Internal Medicine, et al. Comparison of the Birmingham Vasculitis Activity Score and the Five-Factor Score to assess survival in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 550 patients from Spain (REVAS Registry). Arthritis Care Res (Hoboken). 2020;72(7):1001\u201310.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"10","key":"3210_CR19","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1007\/s00296-011-2079-4","volume":"32","author":"JK Ahn","year":"2012","unstructured":"Ahn JK, Hwang JW, Lee J, Jeon CH, Cha HS, Koh EM. Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitides in Korea. Rheumatol Int. 2012;32(10):2979\u201386.","journal-title":"Rheumatol Int"},{"issue":"11","key":"3210_CR20","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s10067-011-1838-7","volume":"30","author":"M Itabashi","year":"2011","unstructured":"Itabashi M, Takei T, Morito T, Yabuki Y, Suzuki H, Ando M, et al. Estimation of BVAS in patients with microscopic polyangiitis in Japan. Clin Rheumatol. 2011;30(11):1499\u2013505.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"3210_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/ard.2008.088096","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, European Vasculitis Study Group, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310\u20137.","journal-title":"Ann Rheum Dis."},{"key":"3210_CR22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s13075-015-0815-y","volume":"17","author":"KE Sada","year":"2015","unstructured":"Sada KE, Yamamura M, Harigai M, Fujii T, Takasaki Y, Amano K, Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan, et al. Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study. Arthritis Res Ther. 2015;17:305.","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"3210_CR23","doi-asserted-by":"publisher","first-page":"e002953","DOI":"10.1136\/rmdopen-2022-002953","volume":"9","author":"M Samson","year":"2023","unstructured":"Samson M, Devilliers H, Thietart S, Charles P, Pagnoux C, Cohen P, et al. Score to assess the probability of relapse in granulomatosis with polyangiitis and microscopic polyangiitis. RMD Open. 2023;9(1):e002953.","journal-title":"RMD Open"},{"issue":"4","key":"3210_CR24","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/acr.20433","volume":"63","author":"R Suppiah","year":"2011","unstructured":"Suppiah R, Judge A, Batra R, Flossmann O, Harper L, H\u00f6glund P, et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener\u2019s granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken). 2011;63(4):588\u201396.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"3210_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2478\/rir-2023-0005","volume":"4","author":"Z Chen","year":"2023","unstructured":"Chen Z, Tian X, Qu J, Chen J, Yang Y, Li J. Development and internal validation of a model to predict long-term survival of ANCA associated vasculitis. Rheumatol Immunol Res. 2023;4(1):30\u20139.","journal-title":"Rheumatol Immunol Res"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03210-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03210-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03210-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T06:03:31Z","timestamp":1700460211000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03210-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3210"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03210-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3354790\/v1","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]},"assertion":[{"value":"14 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adhered to the principles of the Declaration of Helsinki and its amendments. Approval was granted by the Ethics Committee of Osaka Medical and Pharmaceutical University and the Faculty of Medicine (Approval No. 1529), as well as by the individual participating centres, namely Kyoto University (Approval No. R1540) and Osaka Metropolitan University (Approval No. 2021-074). The Ethics Committee of Kyoto University waived the need for patient informed consent given the anonymized nature of the data. Written informed consent was obtained from patients at other participating institutes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TK received payments for lectures from AbbVie, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Pfizer, and Boehringer Ingelheim. SM received a research grant from the Japan Intractable Diseases Research Foundation and payment for lectures from AbbVie. RW received research grants from AbbVie and speaker fees from Asahi Kasei, Chugai, Eli Lilly, GSK, and Sanofi. RH received research grants from GSK and speaker fees from AbbVie, Asahi Kasei, Brystol-Meyers Squibb, Eisai, Eli Lilly, GSK, Kissei, and Pfizer. MH received research grants and speaker fees from AbbVie, Asahi Kasei, Astellas, Brystol Meyers, Chugai, Eisai, Daiichi Sankyo, Eli Lilly, Novartis Pharma, and Tanabe Mitsubishi. TT received research grants and\/or speaker fees from AbbVie, Asahi Kasei, Astellas, Brystol-Meyers Squibb, Chugai, Eisai, Eli Lilly, Janssen Pharma, Nihon Shinyaku, Mitsubishi Tanabe, Takeda, and Pfizer. The other authors (AO, DN, TG, AM, MS, KK, and WY) declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"223"}}